Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Biopharma Presents Data on Its Therapeutic Candidates at Alzheimer's Conference
News Update

Share on Stocktwits


The company discussed both its Alzheimer's disease and ALS programs.

ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) announced in a news release it shared data on its lead candidate PMN310, for Alzheimer's disease, at the annual Alzheimer's Association International Conference (AAIC) held July 14 to 18.

On July 18, the company's chief development officer, Dr. Johanne Kaplan, gave a talk on the therapeutic potential of PMN310 against the toxic oligomer form of amyloid beta, a root cause of Alzheimer's disease. She showed PMN310's ability in vitro to stop the spread and toxicity of amyloid beta's toxic oligomer form, and in vivo, to prevent it from inducing loss of memory and to reduce inflammation and synaptic loss.

She pointed out the drug compares favorably with other amyloid beta-targeted antibodies. PMH310 does not bind to amyloid beta deposits in the brains of Alzheimer's disease patients, and it binds more selectively to the toxic form of amyloid beta.

Kaplan commented in the release about the sentiment at the recent AAIC meeting. "This year's gathering was arguably one of the most significant as the research community pivots from a year of discouragement and failure toward hope," she said. "New, incredibly promising therapy development efforts are underway to target the correct, toxic form of amyloid beta, advance new biomarkers that can better identify promising therapy candidates early and mature understanding of new, emerging targets such as tau and sources of neuroinflammation."

ProMIS made a second presentation at the AAIC conference, it also announced. In a poster presentation on July 17, the company's chief scientific officer, Dr. Neil Cashman, "demonstrated the role of toxic, misfolded TDP43 as a root cause of neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia" and delivered data on how ProMIS' preclinical ALS program selectively targets it, the release noted.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this interview, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS Neurosciences, a company mentioned in this article.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe